Abstract
Interferon (IFN) therapies, including IFN, peginterferon (PEG-IFN) and ribavirin (RBV) plus PEG-IFN combination, are widely used for patients with chronic hepatitis C. We encountered a patient with chronic hepatitis C in whom previous IFN or PEG-IFN alone had not induced type 1 diabetes (T1D), while the addition of RBV to PEG-IFN did induce T1D. The patient had HLA types conferring highly susceptibility to T1D. Thus, adding RBV to PEG-IFN may render chronic hepatitis C patients, with T1D-susceptible HLA types, more prone to developing T1D than IFN or PEG-IFN alone. To prevent T1D development, we recommend HLA typing prior to initiating RBV plus PEG-IFN administration.
Publication types
-
Case Reports
-
Comparative Study
MeSH terms
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 1 / blood*
-
Diabetes Mellitus, Type 1 / chemically induced
-
Drug Therapy, Combination
-
Female
-
Hepatitis C, Chronic / blood*
-
Hepatitis C, Chronic / drug therapy
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage*
-
Interferon-alpha / adverse effects
-
Middle Aged
-
Polyethylene Glycols / administration & dosage*
-
Polyethylene Glycols / adverse effects
-
Recombinant Proteins
-
Ribavirin / administration & dosage*
-
Ribavirin / adverse effects
Substances
-
Blood Glucose
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a